The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 7, 2014, Pages 846-852

  Adelzadeh, L ^a   Jourabchi, N ^a   Wu, J J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VARICELLA ZOSTER VACCINE;

BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG SAFETY; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; INFLAMMATORY BOWEL DISEASES; RISK FACTOR; SPONDYLITIS, ANKYLOSING;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904975793     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12307     Document Type: Review

References (66)

1. Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM,. Biologic therapy in psoriasis: a brief history. II. Cutis 2001; 68: 367-372.
2. Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
3. Schon MP, Boehncke WH,. Psoriasis. N Eng J Med 2005; 352: 1899-1912.
4. Hehlgans T, Pfeffer K,. The intriguing biology of the tumour necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 1-20.
5. Gottlieb AB, Chamian F, Masud S, et al,. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-2729.
6. Zaba LC, Cardinale I, Gilleaudeau P, et al,. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194.
7. Kormeili T, Lowe N, Yamauchi P,. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies, U.S. experiences. Br J Dermatol 2004; 151: 3-15.
8. Abbot Laboratories, North Chicago, IL. Adalimumab (Humira) package insert; 2004.
9. Winterfield L, Menter A,. Infliximab. Dermatol Ther 2004; 17: 409-426.
10. Steinman L,. A rush to judgment on Th17. J Exp Med 2008; 205: 1517-1522.
11. McKenzie BS, Kastelein RA, Cua DJ,. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27: 17-23.
12. Vanden ES, Goriely S, De Wit D, Willems F, Goldman M,. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol. 2005; 35: 469-475.
13. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P,. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-214.
14. + effector memory T cells. J Immunol 2008; 180: 7948-7957.
15. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F,. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949.
16. Wendling D, Streit G, Toussirot E, Prati C,. Herpes zoster in patients taking TNFalpha anatgonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 540-543.
17. Griffiths CE, Strober BE, van de Kerkhof P, et al,. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
18. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
19. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P,. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67: 86-92.
20. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
21. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
22. Van de Kerkhof PC, Segaert S, Lahfa M, et al,. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
23. Gottlieb AB, Matheson RT, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
24. Yang HZ, Wang K, Jin HZ, et al,. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) 2012; 125: 1845-1851.
25. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
26. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
27. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
28. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 6: 31.
29. Leonardi C, Langley RG, Papp K, et al,. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429-436.
30. Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG,. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
31. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
32. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
33. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
34. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-163.
35. Igarashi A, Kato T, Kato M, Song M, Nakagawa H,. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252.
36. Gottlieb AB, Langley RG, Strober BE, et al,. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012; 167: 649-657.
37. Zachariae C, Mork NJ, Reunala T, et al,. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495-501.
38. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-1117.
39. McDonald JR, Zeringue AL, Caplan L, et al,. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-1371.
40. Donahue JG, Choo PW, Manson JE, Platt R,. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-1609.
41. Wolfe F, Michaud K, Chakravarty EF,. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370-1375.
42. Strangfeld A, Listing J, Herzer P, et al,. Risk of herpes zoster in patients with Rheumatoid Arthritis Treated with Anti-TNF-α agents. JAMA 2009; 301: 737-744.
43. Galloway JB, Mercer LK, Moseley A, et al,. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-234.
44. Serac G, Tubach F, Mariette X, et al,. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol 2012; 132: 726-729.
45. Askling J, Fored CM, Brandt L, et al,. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-1344.
46. Failla V, Jacques J, Castronovo C, Nikkels AF,. Herpes zoster in patients treated with biologicals. Dermatology 2012; 224: 251-256.
47. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al,. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-1755.
48. Dreiher J, Kresch FS, Comaneshter D, Cohen AD,. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol 2012; 26: 1127-1132.
49. Winthrop KL, Baddley JW, Chen L, et al,. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-895.
50. Failla V, Castronovo C, Meex C, Nikkels AF,. Protracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administration. Europ J Dermatol 2011; 21: 782-783.
51. Cruz MJ, Baudrier T, Ferreira O, Azevedo F,. Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol 2011; 30: 236-238.
52. Kunz AN, Rajnik M,. Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn's disease: case report of two pediatric patients at one institution. Clin Pediatr (Phila) 2011; 50: 559-561.
53. Arias M, Arias-Rivas S, Dapena D, Mera A,. Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab. Neurologia 2005; 20: 374-376.
54. Nobile S, Catassi C, Felici L,. Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 2009; 15: 101.
55. Chua I, Standish R, Lear S, et al,. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol 2007; 150: 306-311.
56. Kinder A, Stephens S, Mortimer N, Sheldon P,. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26.
57. Baumgart DC, Dignass AU,. Shingles following infliximab infusion. Ann Rheum Dis 2002; 61: 661.
58. Tresch S, Trueb RM, Kamarachev J, French LE, Hofbauer GF,. Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology 2009; 219: 347-349.
59. Izumi A,. Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? Hawaii Med J 2009; 68: 277-278.
60. Failla V, Nikkels AF,. Ustekinumab and herpes zoster. Dermatology 2011; 222: 119-122.
61. Wallis RS,. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8: 601-611.
62. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP,. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
63. Harpaz R, Ortega-Sanchez I, Seward J,. Prevention of herpes zoster. MMWR Morb Mortal Wkly Rep 2008; 50: 1-30.
64. Oxman MN, Levin MJ, Johnson GR, et al,. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
65. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008; 57, 1-30.
66. Zhang J, Xie F, Delzell E, et al,. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-49.